About Us

VectorVision specializes in the standardization of contrast sensitivity, glare sensitivity, low contrast acuity, and ETDRS acuity vision testing. Our patented standardization system provides the practitioner or researcher the ability to delineate very small changes in visual capability, either as compared to the population or from visit to visit. We have made significant strides to develop new and better types of tests during our first 25 years of existence and will continue to make these strides in the future.

drdaveDavid W. Evans, Ph.D, MBA is the founder of VectorVision and the inventor of the CSV-1000. Dr. Evans is internationally known for his work in vision assessment and speaks widely at medical and scientific meetings.

Dr. Evans has also worked as a consultant and has participated in the development of study protocols and/or data analysis for clinical studies sponsored byAMO, Alcon, AcuFocus, Pharmacia, Otsuka, Novartis and others. He has published more than 30 scientific articles and book chapters in the areas of refractive surgery, glaucoma, ocular blood flow and visual function. He also holds 5 patents for optical and vision testing devices. He speaks widely about contrast sensitivity testing, including presentations at American Society of Cataract and Refractive Surgery, European Society of Cataract and Refractive Surgery, Japanese Society of Refractive Surgery and the Chinese Academy of Ophthalmology.

Dr. Evans co-founded an Internet medical marketing communications firm specializing in eye health in 1996, and later co-founded Ceatus Media Group LLC in 2004, for which he currently serves as CEO. Ceatus publishes a variety of consumer health sites catering to eye health, including Refractive Surgery News and Better Vision Guide.

tammyTamara Evans is the co-founder and VP of Marketing of VectorVision, Inc. Ms. Evans has been instrumental in establishing the VectorVision worldwide brand, promoting the use of the CSV-1000 in more than 60 countries. She has brought considerable experience to VectorVision from her positions as product manager at Heidelberg Engineering, Senior Analyst at the Air Force Logistics Command and Director of the Metrics Center of Excellence at Innolog Corp.

Ms. Evans feels very strongly about the impeccable scientific credentials of the VectorVision products and has been a contributing force in both the development of the population norms for the CSV1000E as well as establishing the instrument as the worldwide benchmark for contrast sensitivity testing. The CSV-1000 norms are widely used as a reference for FDA and other clinical trials, and as a basis for more than 200 peer-reviewed papers. In additional to a Bachelor of Science degree in economics from the University of Dayton, Ms. Evans holds an MS degree in Statistics from Wright State University. Ms. Evans also serves as VP of Marketing for Ceatus Media Group LLC located in San Diego, CA.

brianwilsonNote from Vice President, Operations, Brian E. Wilson
At VectorVision, our mission is simple. We produce the best vision testing technology and provide the best customer service in the world. We individually calibrate and inspect each CSV-1000 instrument before it leaves the factory to ensure the highest possible quality. Instruments used for individual practitioners receive the same quality control as those destined for the FDA clinical trials. Any request for information or for technical assistance is typically answered within 24 hours. Our shipping staff can deliver our patented technology directly to the doctor’s office door virtually anywhere in the world, which provides the capability for our clients to deal with the factory, or through a distributor. We have clients in more than 60 countries and have one of the best performance records for any piece of ophthalmic equipment. I take great personal pride in the durability and quality of our equipment. Please contact me at any time if you have a question about our equipment or technology. Also, I would like to thank the many doctors and their staffs who have supported us during the last 25 years.